By Fineline Cube 
Shenzhen YHLO Biotech Co., Ltd. and Beijing Jingyi Bio have formally signed a comprehensive cooperation agreement to accelerate the clinical application and development of neuroimmunology diagnostic technologies. The partnership combines YHLO’s expertise in automated autoimmune testing platforms with Jingyi Bio’s specialized knowledge in neuroimmunology and neurodegenerative disease biomarkers, creating a vertically integrated approach to neurological diagnostics.
Strategic Partnership Framework
| Collaboration Area | YHLO Biotech Contribution | Jingyi Bio Contribution |
|---|---|---|
| Technology Innovation | Automated testing platforms, standardization protocols | Brain neurological biomarker discovery and validation |
| Product R&D | Autoantibody and indirect immunofluorescence testing systems | Clinical translational applications for neuroimmunology |
| Marketing & Commercialization | Established autoimmune testing distribution network | Academic and clinical relationships through Xuanwu Hospital |
| Academic Services | Standardization and intelligence in diagnostic workflows | Deep expertise in neuroimmunology and neurodegenerative diseases |
Company Profiles & Core Competencies
Shenzhen YHLO Biotech Co., Ltd.
- Focus: Autoimmune disease diagnostics with emphasis on autoantibody testing and indirect immunofluorescence
- Innovation: Pioneering automated testing platforms that drive standardization, automation, and intelligence in laboratory workflows
- Market Position: Established leader in traditional rheumatology immunology testing with expanding neurological applications
Beijing Jingyi Bio
- Focus: Neuroimmunology and neurodegenerative diseases with specialized expertise in brain neurological biomarker detection
- Clinical Integration: Strategic collaboration with Xuanwu Hospital of Capital Medical University for clinical validation and translational research
- Technology Platform: Advanced biomarker detection technologies specifically optimized for neurological disorders
Market Impact & Strategic Significance
- Diagnostic Gap Addressed: Current autoimmune testing primarily focuses on rheumatological conditions, leaving neuroimmunological disorders underserved despite growing clinical recognition
- Market Expansion: YHLO’s business presence will extend from traditional autoimmune testing into the rapidly growing neuroimmunology diagnostic market, estimated to reach $2.8 billion globally by 2030
- Competitive Advantage: The integration of Jingyi’s specialized neurological biomarkers with YHLO’s automated platforms creates a unique offering that addresses both technical complexity and workflow efficiency
- Clinical Workflow Enhancement: Automated, standardized neuroimmunology testing will improve diagnostic accuracy, reduce turnaround times, and enable broader adoption in routine clinical practice
Strategic Outlook
The collaboration represents a strategic pivot for YHLO Biotech, leveraging its established autoimmune testing infrastructure to enter the high-growth neuroimmunology segment. By combining Jingyi Bio’s clinical expertise and biomarker portfolio with YHLO’s automation capabilities, the partnership aims to establish new standards for neurological autoimmune diagnostics while accelerating the translation of research discoveries into clinical practice.
Forward-Looking Statements
This brief contains forward-looking statements regarding partnership outcomes, market expansion, and product development. Actual results may differ due to risks including regulatory challenges, competitive dynamics, technology integration complexities, and market adoption rates.-Fineline Info & Tech